［1］中华医学会内分泌学分会免疫内分泌学组. 免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识 (2020)［J］. 中华内分泌代谢杂志, 2021, 37(1): 1-16.
［2］Barroso-Sousa R, Barry W T, Garrido-Castro A C, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis［J］. JAMA Oncol, 2018, 4(2): 173-182.
［3］Lo Preiato V, Salvagni S, Ricci C, et al. Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature［J］. Rev Endocr Metab Disord, 2021, 22(2): 337-349.
［4］de Filette J M K, Pen J J, Decoster L, et al. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review［J］. Eur J Endocrinol, 2019, 181(3): 363-374.
［5］Perdigoto A L, Quandt Z, Anderson M, et al. Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome［J］. Lancet Diabetes Endocrinol, 2019, 7(6): 421-423.
［6］Okamoto M, Okamoto M, Gotoh K, et al. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy［J］. J Diabetes Investig, 2016, 7(6): 915-918.
［7］Matsumura K, Nagasawa K R, Oshima Y, et al. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab［J］. J Diabetes Investig, 2018, 9(2): 438-441.
［8］Yamamoto N, Tsurutani Y, Katsuragawa S, et al. A patient with nivolumab-related fulminant type 1 diabetes mellitus whose serum c-peptide level was preserved at the initial detection of hyperglycemia［J］. Intern Med, 2019, 58(19): 2825-2830.
［9］Greenbaum C J, Beam C A, Boulware D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data［J］. Diabetes, 2012, 61(8): 2066-2073.
［10］Stamatouli A M, Quandt Z, Perdigoto A L, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors［J］. Diabetes, 2018, 67(8): 1471-1480.
［11］Pihoker C, Gilliam L K, Hampe C S, et al. Autoantibodies in diabetes［J］. Diabetes, 2005, 54(Suppl 2): S52-S61.
［12］Nan X X, Li X, Xiang Y F, et al. Screening strategy for islet autoantibodies in diabetes patients of different ages［J］. Diabetes Technol Ther, 2022, 24(3): 212-219.
［13］Matsuura N, Koh G, Konishi C, et al. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC［J］. Cancer Immunol Immunother, 2018, 67(9): 1417-1424.
［14］Luo J M, Feng J G, Liu C Y, et al. Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases［J］. J Int Med Res, 2022, 50(9): 3000605221121940.
［15］Cheema A, Makadia B, Karwadia T, et al. Autoimmune diabetes associated with pembrolizumab: a review of published case reports［J］. World J Oncol, 2018, 9(1): 1-4.
［16］ A J K, Norcross A J, Dix R J, et al. The prevalence of insulin autoantibodies at the onset of type 1 diabetes is higher in males than females during adolescence［J］. Diabetologia, 2003, 46(10): 1354-1356.
［17］Ziegler A G, Hummel M, Schenker M, et al. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study［J］. Diabetes, 1999, 48(3): 460-468.
［18］Bingley P J, Bonifacio E, Mueller P W. Diabetes antibody standardization program: first assay proficiency evaluation［J］. Diabetes, 2003, 52(5): 1128-1136.
［19］Irvine W J, Sawers J S, Feek C M, et al. The value of islet cell antibody in predicting secondary failure of oral hypoglycaemic agent therapy in diabetes mellitus［J］. J Clin Lab Immunol, 1979, 2(1): 23-26.
|
